TIDMGWP

GW Pharmaceuticals PLC

08 May 2014

GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference

London, UK, 8 May 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV on Tuesday, 13 May, 2014 at 4:20 p.m. PT (1:20 p.m. ET). The conference will be held at the Encore at Wynn Las Vegas.

A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

 
 GW Pharmaceuticals plc                        (Today) +44 20 3727 1000 
 Justin Gover, Chief Executive Officer         (Thereafter) + 44 1980 
                                                557000 
 Stephen Schultz, VP Investor Relations        917 280 2424 / 401 500 
  (U.S.)                                        6570 
 
 FTI Consulting (Media Enquiries) 
 Ben Atwell / Simon Conway / John Dineen 
  (UK)                                         + 44 20 3727 1000 
 Robert Stanislaro (U.S.)                      212 850 5657 
 
 Trout Group, LLC (U.S. investor relations) 
 Todd James / Chad Rubin                       646 378 2900 
 
 Peel Hunt LLP (UK NOMAD)                      +44 20 7418 8900 
 James Steel / Clare Terlouw

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALLFLEEAITIIS

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Gw Pharmaceuticals Charts.
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Gw Pharmaceuticals Charts.